This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XTL Biopharmaceuticals Ltd. Names Dr. Ben-Zion Weiner To Its Board Of Directors

HERZLIYA, Israel, April 17, 2012 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced yesterday that Dr. Ben-Zion Weiner, Ph.D., has been named as director of the Company's board of directors.

Since 2012, Dr. Weiner serves as Special Advisor to the Chief Executive Officer of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA, TASE: TEVA.TA). Dr. Weiner brings to XTL his vast experience in pharmaceutical development, from R&D to regulatory approval. Dr. Weiner has been with Teva for 36 years.

"I am very pleased to have joined XTL as member of the board of directors and I will use my R&D expertise in the product development of the Company," said Dr. Weiner.

Dr. Weiner received his Ph.D. in chemistry from the Hebrew University of Jerusalem, where he also earned B.Sc. and M.Sc. degrees, followed by a post-doctoral fellowship at Schering-Plough Corporation in the United States. He was granted the Rothschild Prize for Innovation/Export twice, in 1989 for the development of Alpha D3 for dialysis and osteoporosis, and in 1999 for the development of Copaxone® for multiple sclerosis.

David Grossman, XTL's CEO commented "Dr. Weiner brings with him 40 years of drug development experience in the pharmaceutical industry, with large number of New Drug Application approvals under his leadership. We are very pleased that he joined our board, and believe his experience will be extremely valuable as we progress with our clinical development programs."  

About XTL Biopharmaceuticals, Ltd. ("XTL")

XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs